(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Spanish woman, 25, dies by legal euthanasia in case that drew national spotlight - 2Key Business Regulations to Consider While Arranging Your Independent venture
- 3Jury says Johnson & Johnson owes $40 million to 2 cancer patients who used talcum powders
- 4At least 36 dead in major fire in Hong Kong residential blocks
- 5Step by step instructions to Pick A Pre-owned vehicle Stage
- Manual for Financial plan Agreeable PC
- 'Wicked: For Good' was filmed at this surreal National Park in Egypt
- New York to require social media platforms to display mental health warnings
- Interstellar comet 3I/ATLAS isn't an alien spacecraft, astronomers confirm. 'In the end, there were no surprises.'
- The Main 15 Applications for Efficiency and Association
- REWE launches seventh Pick&Go test store in Hanover
- Ministry: New German petrol price regulation takes effect on April 1
- Astronauts head home early after medical issue
- Who is Adm. Frank 'Mitch' Bradley and what does he have to do with the Venezuela boat strikes?
